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Abstract
Background: Fatigue is a prominent quality of life concern among cancer patients who have
undergone allogeneic hematopoietic cell transplantation (HCT). The high percentage of HCT
patients reporting fatigue concerns warrants investigation into factors that may contribute to or
alleviate fatigue. The present study sought to elucidate relationships among fatigue and
behavioral factors including sleep disruption and sedentary activity.
Method: Allogeneic HCT recipients who were one to five years post-transplant were invited to
participate in the present study. Participants wore an actigraph assessing sleep efficiency and
sedentary behavior for one week, completed daily assessments of fatigue and sleep during the
same period, and completed self-report questionnaires of fatigue (summary fatigue), sleep, and
sedentary behavior on day seven of the study.
Results: Eighty-two allogeneic HCT recipients (age M = 56, 52% female) were enrolled and
provided complete data. Forty-five percent of participants met criteria for clinically significant
fatigue. Summary fatigue, but not aggregated daily fatigue, predicted sleep efficiency; neither
summary nor momentary fatigue predicted sedentary behavior. Sleep disruption during the
previous night and sedentary behavior during the day were related to evening reports of daily
average fatigue but not daily momentary fatigue.
Conclusion: Results from the present study suggest that nearly half of HCT recipients continue
to experience clinically significant fatigue one to five years post-transplant. Results from the
daily analysis suggest that patients who sleep better the previous night and are less sedentary that
day report less fatigue at the end of the day, which is a finding that warrants replication and
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further study. Finally, findings suggest that a daily assessment methodology may be more useful
under circumstances in which there is greater daily variability in fatigue.
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Introduction
Cancer-related fatigue has been defined as “a distressing, persistent, subjective sense of
physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer
treatment that is not proportional to recent activity and interferes with usual functioning” (NCCN
Guidelines, 2017). Fatigue is one of the most commonly reported symptoms before, during, and
after hematopoietic cell transplant or HCT, an intensive therapy used to treat hematologic
malignancies including leukemia, lymphoma, and multiple myeloma (Cohen et al., 2012; Grulke,
Albani, & Bailer, 2012; Anderson et al., 2007; Gielissen et al., 2007). This is particularly true for
patients undergoing allogeneic HCT (involves receipt of donor cells), who are at risk for a range
of side-effects following transplant, including graft-versus-host disease (GVHD) in which
grafted donor cells attack host tissue. Chronic GVHD has been shown to moderate fatigue
among allogeneic transplant recipients during the first year following transplant (Nelson et al.,
2014) and tends to be most prevalent between one to five years post-transplant. Fatigue has been
shown to be significantly worse among transplant patients in the post-treatment period compared
to non-cancer controls (Hacker et al., 2016; Hann et al., 1998). Previous studies have
documented that as many as 81% of transplant recipients report clinically significant fatigue at
day 100 post-transplant (Bevans et al., 2008), with between 11 to 31% reporting clinically
significant fatigue three or more years after transplant (Jim et al., 2016; Hjermstad et al., 2004).
Gielissen and colleagues (2007) investigated the percentage of transplant recipients meeting an
established criterion for severe fatigue. They found that 35% of transplant recipients who were 1
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to 22 years post-transplant met criteria for severe fatigue and that fatigue severity was not related
to time since transplant (Gielissen et al., 2007).
Measurement of Fatigue
Like many symptoms, fatigue is a subjective state and current methods of fatigue
measurement rely on patient self-report. Clinicians and researchers most often utilize brief,
retrospective, self-report questionnaires to assess fatigue. Unidimensional fatigue scales typically
provide data only on the intensity of fatigue, whereas multidimensional scales assess fatigue in a
variety of dimensions. For example, the Fatigue Symptom Inventory (FSI) is a commonly used
multidimensional fatigue assessment measure that provides data on fatigue severity, interference,
and duration (Hann et al., 1998). The majority of what is known about cancer-related fatigue is
based on retrospective self-report methodology. That is, respondents are typically asked to
provide ratings of their fatigue over a previous period of time, such as the past week. As
described next, these retrospective self-report methods have a number of limitations.
Problems with Retrospective Self-Report Methods
Recall is a central component of retrospective self-report methodology. However,
cognitive science research suggests that much of lived experience is not retained in memory. In
contrast to emotionally salient or unique experiences, mundane states and events are less likely
to be encoded, consolidated, stored, and retrieved (Bradburn, Rips, & Shevell, 1987). Therefore,
recall may largely represent an individual’s attempt to reconstruct experiences through the use of
heuristic strategies, which are prone to bias. Adding to this complexity, mental state at the time
of information retrieval can also influence memory accessibility. For example, Sprangers and
colleagues (1999) demonstrated that the trajectory of pre- to post-radiation fatigue influenced
post-radiation recall of pre-radiation fatigue. Specifically, patients who demonstrated a
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decreasing trajectory of pre- to post-radiation fatigue reported higher pre-radiation fatigue on a
recall assessment than was actually reported at pre-radiation (Sprangers et al., 1999). Findings
such as these have been used to argue that autobiographical memory is subject to random error
and that systematic bias adversely impacts patient self-report (Shiffman, Stone, & Hufford,
2008).
Another key concern with retrospective self-reported data is that this methodology asks
patients to report on experience over some specified period of time. Ideally, patients would recall
the particular queried symptom experience during the specified time frame, aggregate and
summarize those experiences, and produce an average score representing their experience during
that period. However, cognitive science has determined that humans are not well-suited to this
highly systematized process. Rather than engage in this process, individuals tend to use shortcuts to arrive at an answer. In one such short-cut, termed the availability heuristic, individuals
make judgments about the frequency of experiences based on the availability or ease of retrieval
(Tversky & Kahneman, 1973). Those events that are easy to retrieve are deemed more frequent.
While heuristics such as these are time and “processing power” savers, the bias inherent in these
strategies can have a detrimental impact on the validity of retrospective patient-reported data that
is aggregated over time.
While all of these sources of bias should be acknowledged when using traditional
retrospective self-report methods, it is important to recognize that these memory processes
operate outside of conscious awareness and do not represent deceptive intent. Social desirability
bias and deception are additional processes that may influence patient self-report. In summary,
autobiographical memory and recall processes are prone to bias, which can adversely impact the
validity of retrospective self-report ratings.
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Alternative Symptom Measurement Strategies
Given the concerns that have been raised about retrospective self-report methods, it is
worth considering newer, alternative methods of measuring symptoms such as cancer-related
fatigue. These methods are primarily comprised of “real-time” and “near-real-time” data
collection. One such method, Ecological Momentary Assessment, also referred to as EMA,
represents a potentially valuable alternative approach to symptom data collection. EMA has been
defined as a group of “methods using repeated collection of real-time data on subjects’ behavior
and experience in their natural environments” (Shiffman, Stone, & Hufford, 2008). Core features
of EMA include data collection in real-world environments, focus on the current or very recent
state of the participant, strategic selection of moments to assess, and repeated sampling over
time. While these features are characteristic of EMA studies, implementation is heterogeneous
with variations in EMA content, mode of delivery, and schedule.
EMA approaches offer numerous advantages over retrospective self-report methods.
Shiffman, Stone, & Hufford (2008) note that EMA approaches produce data that are potentially
more reliable than retrospective self-report methods because EMA collects real-time data with
repeated sampling over time and does not ask patients to retrospectively aggregate experience. In
addition, EMA maximizes ecological validity, meaning that the data collected are more reflective
of real-world patient experience. Of particular importance, EMA approaches focus on the current
or very recent state of the participant, thus minimizing autobiographical memory processes,
which can introduce bias. Therefore, EMA represents methodology that is complementary to
retrospective patient self-report and which may be better able to address certain research
questions.
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EMA With HCT Patients
Surprisingly, HCT is one of the few cancer contexts where electronic EMA methods have
been used to measure fatigue (Hacker et al., 2007). Hacker and colleagues (2007) utilized EMA
to assess fatigue among 20 HCT recipients for three days before and for three days following
transplantation (i.e., receipt of stem cell product). This study obtained impressively high
compliance rates, demonstrating that EMA methods are feasible even in the acute period
surrounding HCT (Hacker et al., 2007). Unfortunately, this study did not assess fatigue using a
retrospective self-report measure, and therefore, does not address questions regarding the
comparability of the two assessment methods. Moreover, EMA has yet to be used to address at
least one key question in the HCT setting; that is, how do behavioral factors such as sleep
disruption and physical activity contribute to fatigue?
Relationship Between Fatigue and Behavior
There are thought to be complex, bidirectional relationships between fatigue and sleep in
people with cancer (Minton & Stone, 2012; Rahman, Burton, Galbraith, Lloyd, & VollmerConna, 2011; Alexander, Minton, Andrews, & Stone, 2009). For example, sleep disturbances
could cause fatigue during the day, or conversely fatigue during the day could lead to
maladaptive sleep behaviors such as daytime napping and difficulties sleeping at night. Similar
relationships can be described between fatigue and activity (i.e., physical inactivity could cause
fatigue during the day or fatigue could lead to physical inactivity).
Research into the relationships of fatigue with sleep and physical activity in people with
cancer has typically relied on retrospective self-report ratings of all three constructs. This
literature has consistently demonstrated strong relationships of physical activity and sleep with
fatigue (Peters, Goedendorp, Verhagen, Bleijenberg, van der Graaf, 2016; Ratcliff, Lam, Arun,
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Valero, & Cohen, 2014; Peters, Goedendorp, Verhagen, van der Graaf, & Bleijenberg, 2014;
Pertl, Hevey, Collier, Lambe, & O’Dwyer, 2014; Ng et al., 2005; Jacobsen et al., 1999). For
example, breast and prostate cancer patients who reported minimal physical activity had greater
fatigue than those with high physical activity levels (Humpel & Iverson, 2010). Poor sleep
quality was also associated with greater fatigue in this study.
While a large literature has demonstrated links between self-reported physical activity
and fatigue and between self-reported sleep and fatigue, this literature is not without drawbacks.
For instance and as already noted, a host of factors contribute to bias in retrospective self-reports.
A review of self-reported physical activity in particular found that measurement methods have
considerable impact on the observed level of activity, with self-report measures yielding levels
that are both higher and lower than levels obtained with objective methods of measurement
(Prince et al., 2008). Similarly, the lack of a relationship between self-reported and objectively
measured sleep is one of the most published findings in sleep medicine (Buysse et al., 2008).
These issues lead to questions about the validity and precision of self-reported behavior.
Many of these problems can be overcome through direct observation of behavior.
Advances in technology have produced options for aiding scientists and clinicians in “observing”
behavior. For instance, actigraphy involves the objective measurement of activity by means of an
accelerometer that records and averages physical movement (Ancoli-Israel et al., 2003). It has
been successfully used to measure sleep/wake patterns in breast and gynecologic cancer patients
(Liu et al., 2013; Ancoli-Israel et al., 2006; Jim et al., 2011), patients with advanced cancer (Ma,
Chang, & Lin, 2014), and autologous HCT patients (Nelson et al., 2017). It has also been used
successfully to measure activity and sedentary behavior among cancer patients (Broderick, Ryan,
O’Donnell, Hussey, 2014; Maddocks & Wilcock, 2012; Jim et al., 2011).
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Actigraphy to Measure Sleep Disruption and Sedentary Behavior
Research investigating links between objectively measured behavior and self-reported
fatigue has produced conflicting results. Several studies that have investigated these relationships
do not support a link between objectively measured behavior (e.g., mean daytime activity) and
fatigue as measured by retrospective self-reports (Yennurajalingam et al., 2016; Servaes,
Verhagen, & Bleijenberg, 2002; Fernandes et al, 2006). For example, Fernandes and colleagues
(2006) determined that fatigue severity rated for the past week was not related to actigraphy
measured activity, sleep, or circadian rhythm impairments among female inpatients with cancer.
Other studies have yielded mixed findings (Miaskowski et. al., 2011; Minton & Stone, 2012;
Berger et al., 2007). For example, fatigue severity over the current day was related to acrophase,
a circadian rhythm variable that measures the time of day of the peak of the rhythm, but not to
other sleep, activity, or circadian rhythm measures among women prior to adjuvant breast cancer
chemotherapy (Berger et al., 2007). Minton & Stone (2012) examined self-reported and
objective measures of sleep and activity among survivors of breast cancer who were split into
two groups, women who met criteria for cancer-related fatigue syndrome in the past month and
those who did not. These authors found differences between groups on self-reported sleep, as
well as differences in objectively measured daytime activity; however, no differences were
observed with objective measures of sleep.
A third set of studies yielded more supportive evidence regarding links between
objectively measured behavior and self-reported fatigue among cancer populations (Berger et al.,
2010; Winters-Stone, Bennett, Nail, & Schwartz, 2008; Mallinson, Cella, Cashy, & Holzner,
2006; Ancoli-Israel, Moore, & Jones, 2001; Berger & Higginbotham, 2000). Liu and colleagues
(2012) found that fatigue severity over the past week was positively associated with subjective
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sleep scores and actigraphy measured total naptime and was negatively associated with total
wake time during the day among newly diagnosed women with stage I-III breast cancer.
Similarly, at the level of daily experience, it has been demonstrated that actigraphy measured
sleep disturbance during chemotherapy can initiate a symptom cascade leading to increased
fatigue as measured by daily ratings and increased depressive symptoms (Jim et al., 2013). In
addition, a recent study found a positive relationship between cancer-related fatigue and sleep
time and a strong inverse relationship between cancer-related fatigue and physical performance
as measured by smart-bracelet devices among patients with metastatic pancreatic cancer (Shen et
al., 2016). Moreover, objectively measured increases in physical activity have been associated
with decreases in self-reported fatigue among patients receiving radiation treatment (Sarna &
Conde, 2001).
While accumulating evidence linking behavioral factors to fatigue appears promising, it
is unclear why evidence has been so mixed. Differences in cancer type, treatment received, time
of assessment (e.g., before, during, or after treatment), method of sleep and activity assessment
(i.e., objective vs. self-report), and methods of fatigue measurement (i.e., daily vs. retrospective)
are likely important and may partially account for varying evidence. Moreover, objective indices
are capable of producing a diverse array of sleep and activity variables. Therefore, it is important
that researchers carefully choose sleep and activity variables apriori based on theory and a close
review of previous literature.
As already discussed, processes such as memory bias and heuristics influence reports of
symptoms such as fatigue. It may be that these processes, in combination with the temporal gap,
which occurs between objectively recording behavior and assessing symptoms with summary
measures, could partially account for the observed mixed evidence. If this is the case, then EMA
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symptom assessment offers a temporal advantage of less time between measurement and the
objectively assessed behavior, as well as the benefit of a reduced bias of confounding memory,
heuristic, or other processes. In this way, an EMA approach to assessing fatigue may yield more
consistent evidence for relationships of self-reported fatigue with objective measures of sleep
disturbance and sedentary activity. The implications of this are likely multifactorial and may
include provision of a more sophisticated understanding of the contribution of behavioral factors
to cancer-related fatigue as well as improved identification of intervention targets for addressing
cancer-related fatigue.
Considerations for Research Within the Setting of HCT
While relationships between self-reports of sleep, activity, and fatigue are well
characterized, relationships between objectively measured sleep and activity with self-reported
fatigue are not well understood. Moreover, even less is known about the impact of daily sleep
and activity on daily fatigue. Given these key unanswered questions, the present study
characterized fatigue among allogeneic HCT patients and investigated relationships of sleep and
sedentary behavior with fatigue. Fatigue was assessed in two ways. First, patients were asked to
provide “daily fatigue” ratings, which were collected using an EMA approach every day for the
seven-day study period. For select statistical analyses, these daily fatigue ratings were averaged
across the seven-day study period to create an “aggregated daily fatigue” variable. Second,
patients provided “summary fatigue” ratings, which were collected using a validated
retrospective self-report questionnaire completed at the end of the seven-day study period.
During this seven-day study period, sleep disruption and sedentary behavior were assessed
primarily by actigraphy and used to create aggregated seven-day measures of sleep disruption
and sedentary behavior. These data were used to conduct between-persons analyses to examine
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the extent to which aggregated daily fatigue accounts for additional variance in aggregated sleep
disruption and sedentary behavior beyond summary fatigue, as well as the extent to which
summary fatigue accounts for additional variance in aggregated sleep disruption and sedentary
behavior beyond aggregated daily fatigue.
In addition to the approaches described above, exploratory analyses were conducted that
take a within-persons perspective to the interrelationships between sleep disruption, sedentary
behavior, and fatigue. The advantage of the within-persons approach is that unlike the betweenpersons approach that compares a person to others, a within-person approach evaluates outcomes
or predictors in relation to themselves (Curran & Bauer, 2011). Thus, using this method, we were
able to evaluate whether a person is likely to rate themselves as more fatigued after nights with
greater sleep disruption, as compared to nights when their sleep is less disrupted. To begin to
disentangle the complex relationships between sleep disruption, sedentary behavior, and fatigue,
the intraindividual variation in the association between these variables over the seven-day study
period was explored. The data collected were used to address the following aims and hypotheses.
Aims & Hypotheses
Aim 1: To characterize the prevalence and daily variability of fatigue among allogeneic
HCT survivors. Univariate relationships between all fatigue variables, sleep disruption, and
sedentary behavior were also characterized.
Aim 2: To investigate the relative contribution of aggregated daily fatigue and summary
fatigue to aggregated sleep disruption.
Hypothesis 2a: Aggregated daily fatigue was expected to account for additional variance in sleep
disruption above and beyond the influence of summary fatigue.
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Hypothesis 2b: Summary fatigue was expected to account for additional variance in sleep
disruption above and beyond the influence of aggregated daily fatigue.
Aim 3: To investigate the relative contribution of aggregated daily fatigue and summary
fatigue to aggregated sedentary behavior.
Hypothesis 3a: Aggregated daily fatigue was expected to account for additional variance in
sedentary behavior above and beyond the influence of summary fatigue.
Hypothesis 3b: Summary fatigue was expected to account for additional variance in sedentary
behavior above and beyond the influence of aggregated daily fatigue.
While positive relationships were expected between both daily fatigue and summary
fatigue with objectively measured sleep disruption and sedentary behavior consistent with review
of the literature, daily fatigue was expected to demonstrate a more consistent pattern of
significant relationships with sleep disruption and sedentary behavior than summary fatigue.
Aim 4: To explore whether sleep disruption during the previous night and sedentary
behavior during the day were related to evening reports of fatigue.
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Method
Participants
The study sample included adults who underwent an allogeneic HCT at Moffitt Cancer
Center for treatment of a hematologic disease. Eligible participants: 1) were diagnosed with a
hematologic malignancy, 2) underwent an allogeneic HCT approximately 1 to 5 years prior to
study enrollment, 3) were ≥18 years of age, 4) had no history of other cancers other than nonmelanoma skin cancer, 5) had no evidence of disease progression at the time of study enrollment,
6) had ambulatory patient status at the time of study enrollment, 7) had internet access, 8) were
able to speak and read English, and 9) were able to provide informed consent.
Procedures
Study eligibility was determined through consultation with physicians, clinical staff,
medical record and registry data review. Eligible patients returning to clinic for an appointment
were approached during their clinic visit and had the study protocol explained to them. Those
who agreed to participate signed an informed consent form. They were then given an actigraph,
instructions for completing an electronic web-based daily log and study questionnaire, and a
postage-paid envelope. Participants wore the actigraph for seven consecutive 24-hour periods
and completed a daily log of their sleep and fatigue during that time. Access to the electronic
web-based daily log was texted to participants at 6 pm each evening and they were informed that
they had until 9 pm each evening to complete the log. Participants completed the electronic study
questionnaire on day 7 of the study. Participants returned all study materials in the postage-paid

12

envelope. Relevant clinical information was collected with the assistance of the Moffitt Bone
Marrow Transplant Registry and medical record review.
Measures (see Appendix).
Demographic characteristics. Participants completed a standardized self-report form
assessing demographics including age, gender, race, ethnicity, education, income, marital status,
and employment status, as well as height and weight as part of the study questionnaire.
Participants also completed a self-report version of the ECOG performance status scale (Oken et
al., 1982).
Summary fatigue. Participants completed the Fatigue Symptom Inventory (FSI) on the
final day of the study. The FSI is a 14-item self-report measure of fatigue during the past week
assessing three domains of fatigue: severity, interference, and duration (Hann et al., 1998).
Fatigue severity is a composite of the average of four items assessing the most, least, and average
in the past week, and current level of fatigue experienced. The fatigue interference subscale
consists of the average of seven items assessing fatigue interference in the past week with
general level of activity, ability to bathe and dress, normal work activity, ability to concentrate,
relations with other people, and enjoyment of life. Fatigue duration consists of the number of
days fatigued and the amount of time fatigued per day in the past week. Each item is rated on an
11-point Likert scale from 0 to 10 with higher scores indicating greater fatigue. Analyses focused
on the composite fatigue severity score. Scores of ≥ 4 on the average of the fatigue severity items
are indicative of clinically meaningful fatigue according to National Comprehensive Cancer
Network guidelines (NCCN Guidelines, 2017). The FSI is a valid and reliable measure among
cancer populations (Donovan & Jacobsen, 2010; Hann et al., 1998) with a reliability coefficient
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of  = .91 for the severity subscale,  = .93 for the interference subscale, and  = .77 for the
duration subscale in the present study.
Daily fatigue. Participants provided daily fatigue ratings at the end of the day for 7 days
through the use of an electronic diary. Questions were adapted from the FSI and participants
were asked to rate: their level of fatigue right now (momentary fatigue), their peak fatigue during
the day (most fatigue), their average fatigue during the day (average fatigue), and how much
fatigue interfered with their activities during the day (fatigue interference). Of these items,
analyses focused on participant ratings of “level of fatigue right now” as the primary daily
fatigue outcome of interest. Each item was rated on an 11-point Likert scale from 0 to 10 with
higher scores indicating greater fatigue or greater interference from fatigue. Participants were
asked to record their daily fatigue ratings each evening between 6 and 9 pm. Participants
received daily standard text messages granting access to the log and reminding them to complete
their fatigue ratings. Aggregated scores were created by averaging scores for each item over the
seven-day study period.
Sleep disruption. Sleep disruption was measured objectively using the ActiGraph GT9X
Link (Pensacola, FL) and was used to objectively quantify sleep patterns. Participants were
asked to wear the actigraph on their non-dominant wrist continuously for a seven-day period.
Data from the actigraph was downloaded and analyzed using ActiLife v6.13.3 (ActiGraph, LLC,
Pensacola, Florida). All downloaded data first underwent Wear Time Validation, which is a tool
in ActiLife that flags periods of non-wear for further analysis. These periods were reviewed and
scored as wear or non-wear time according to a pre-determined set of rules and accepted
standards. Sleep indices were calculated using the Cole-Kripke algorithm in combination with
daily patient sleep logs of bed and wake times. The primary sleep variable of interest for the
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analyses was sleep efficiency (i.e., the percentage of time spent sleeping in relation to time spent
in bed). Other variables that were explored included: sleep onset latency (SOL, i.e., the amount
of time taken to fall asleep), wake after sleep onset (WASO, i.e., minutes awake after an
extended period of sleep), and total sleep time (TST, i.e., the time spent asleep at night) (Berger
et al., 2008). Aggregated sleep efficiency, which was created by averaging daily sleep efficiency
over the seven-day study period, was used as an outcome for Aims 2 and 3 of the study. Daily
sleep efficiency was used as a predictor for Aim 4 of the study.
Sleep disruption was also measured subjectively using the Pittsburgh Sleep Quality
Inventory (PSQI). Participants completed the PSQI on the final day of the study. The PSQI is a
19-item self-report measure of sleep disruption during the past week assessing seven domains
and providing a global score. Higher scores indicate greater sleep disruption. Analyses focused
on the global score. Scores of ≥ 5 on the global sleep scale are indicative of clinically meaningful
sleep disturbance (Buysse, Reynolds, Monk, Berman, & Kupfer, 1989). The PSQI is a valid and
reliable measure among cancer populations (Beck, Schwartz, Towsley, Dudley, & Barsevick,
2004) with an overall reliability coefficient of  = .87 for the global sleep scale in the present
study.
Sedentary behavior. The ActiGraph GT9X Link (Pensacola, FL) was also used to
objectively quantify sedentary behavior. Data from the actigraph was downloaded and analyzed
using ActiLife v6.13.3 (ActiGraph, LLC, Pensacola, Florida). All data first underwent Wear
Time Validation, described above. Sedentary behavior indices were then calculated using the
Freedson Adult (1998) algorithm which compares actigraph-derived activity values to the
following cut points for activity classification: Sedentary 0 – 99, Light 100 – 1951, Moderate
1952 – 5724, Vigorous 5725 – 9498, and Very Vigorous 9499 and above. The primary sedentary
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behavior measure of interest was sedentary time or the percentage of time spent engaging in
sedentary activity. Aggregated sedentary behavior, which was created by averaging daily
sedentary time over the seven-day study period, was used as an outcome for Aims 2 and 3 of the
study. Daily sedentary time was used as a predictor for Aim 4 of the study.
Subjective reports of sedentary behavior were also assessed using the Marshall Sitting
Questionnaire (MSQ). Participants completed the MSQ on the final day of the study. The MSQ
is a 5-item self-report measure of sitting during the past week and patients are asked to estimate
how much time they spend sitting on an average weekday and on an average weekend day.
Higher scores indicate greater time spent sitting. Calculation of a summary score was planned for
the purposes of this project. The MSQ is a valid and reliable measure and has been used to assess
sedentary behavior among cancer populations (Boyle, Lynch, Courneya, & Vallance, 2015).
Patients also completed an activity report on the last day of the study to aid in
understanding of the types of activities patients generally engaged in. This activity questionnaire
included seven questions, one for each day of the study, about the main type of activity
participated in each day. Participants could choose one of five options including: working
outside the home, working within the home (at home job), leisure activities outside the home,
leisure activities within the home, or other: please describe. For the purposes of the present
study, frequencies were tabulated to determine the primary types of activities participants were
engaged in throughout the study period.
Symptoms. Given the relationship between cGVHD and fatigue among allogeneic HCT
recipients, participants completed the Lee Symptom Scale on the final day of the study. The Lee
Symptom Scale is a 30-item scale assessing cGVHD symptom burden in seven areas (e.g., eyes
and mouth, skin). For the purposes of this study, the scale was keyed to the past week. Each item
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is rated on a 5-point Likert scale from 0 to 4 with higher scores indicating greater symptom
burden. The Lee Symptom Scale is a valid and reliable measure among allogeneic HCT
populations (Lee, Cook, Soiffer, & Antin, 2002) with a reliability coefficient of  = .85 in the
current study.
Participants also completed the Functional Assessment of Cancer Therapy Bone Marrow
Transplant specific subscale (FACT-BMT) on the final day of the study. The FACT-BMT is a
23-item scale assessing symptoms and concerns common to transplantation. The FACT-BMT
was used for descriptive purposes. The FACT-BMT is valid and reliable among allogeneic
transplant patients (McQuellon et al., 1997) with a reliability coefficient of  = .78 in the current
study.
Medical characteristics. Medical characteristics were collected with the aid of the Moffitt
Bone Marrow Transplant Registry and abstracted via medical record review (e.g., cancer
diagnosis, donor type, ablation, time since transplant, etc).
Statistical Analyses
Descriptive statistics (means, standard deviations, ranges, frequencies) were used to
characterize the sample. In those cases where participants missed ≤ 20% of items on an
individual scale, the participant’s available data was used to calculate an item-level mean value
for imputation. Distribution normality of scaled scores was evaluated (skew and kurtosis value
+/- 2). Scaled scores for the present study’s main predictor variables and outcomes met criteria
for normal distribution. To address Aim 1, descriptive statistics (e.g., means, standard deviations,
and frequencies) were used to characterize the prevalence and daily variability of fatigue. Levels
of clinically significant fatigue were also examined using frequencies with the cut-offs
previously specified. Finally, Pearson correlation coefficients were examined to determine
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relationships among aggregated daily fatigue, summary fatigue, sleep disruption, and sedentary
behavior.
In addition, and prior to performing the primary analyses, Pearson correlations were used
to confirm relationships between subjective sleep disruption as measured by the PSQI global
sleep score and aggregated daily and summary fatigue. Pearson correlations were also planned to
confirm relationships between self-reported sedentary behavior as measured by the MSQ and
aggregated daily and summary fatigue. These analyses were planned to confirm expected
relationships and aid in explaining the pattern of observed findings.
To address Aim 2, hierarchical multiple regression analyses were planned to explore the
incremental and combined variance accounted for by aggregated daily fatigue versus summary
fatigue in predicting sleep disruption. To accomplish this, two models were planned. In the first
model, all significant demographic and clinical factors would be entered on the first step,
summary fatigue would be entered on the second step, and aggregated daily fatigue would be
entered on the third and final step. This set of analyses was planned to determine whether
aggregated daily fatigue as measured by EMA contributes any additional variance above and
beyond the influence of summary fatigue. In the second model, all significant demographic and
clinical factors would be entered on the first step, aggregated daily fatigue would be entered on
the second step, and summary fatigue would be entered on the third and final step. This set of
analyses was planned to determine whether summary fatigue accounts for unique variance above
and beyond the influence of aggregated daily fatigue in predicting sleep disruption.
To address Aim 3, hierarchical multiple regression analyses were planned to explore the
incremental and combined variance accounted for by aggregated daily fatigue versus summary
fatigue in predicting sedentary behavior. These analyses parallel the structure of those described
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in Aim 2. In the first model, all significant demographic and clinical factors would be entered on
the first step, summary fatigue would be entered on the second step, and aggregated daily fatigue
would be entered on the third and final step. This set of analyses was planned to determine
whether aggregated daily fatigue as measured by EMA contributes any additional variance above
and beyond the influence of summary fatigue. In the second model, all significant demographic
and clinical factors would be entered on the first step, aggregated daily fatigue would be entered
on the second step, and summary fatigue would be entered on the third and final step. This set of
analyses was planned to determine whether summary fatigue accounts for unique variance above
and beyond the influence of aggregated daily fatigue in predicting sedentary behavior.
To address Aim 4, multi-level models using SAS PROC MIXED were created to address
the hypothesis that daily sleep disruption or sedentary behavior as measured by actigraphy would
be related to daily fatigue. These analyses use a time-lagged approach. In the case of sleep
disruption, this approach allows investigation into whether sleep disruption as measured by
actigraphy during the previous night predicts daily fatigue ratings obtained the following
evening. In the case of sedentary behavior, this approach allows investigation of whether daily
sedentary behavior as measured by actigraphy predicts daily fatigue ratings obtained that
evening. An advantage of these models is the ability to include all participants regardless of
whether complete data are available. Therefore, these analyses included all participants who
contributed at least three days of daily fatigue and actigraphy data. Models 1 – 4 were “empty
models” that included one of the following: daily outcome (momentary fatigue or average
fatigue) or daily predictor (sedentary behavior or sleep efficiency). Model 5 included either
sedentary behavior or sleep efficiency, each centered at the sample mean, as predictors of daily
fatigue. These models allow investigation into whether sedentary behavior during the day and
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sleep efficiency the previous evening predicts daily fatigue at the group level. Model 6 included
either sedentary behavior or sleep efficiency, each centered at the person mean, as predictors of
daily fatigue. These models were the focus of Aim 4 and allow investigation into whether
sedentary behavior during the day and sleep efficiency the previous evening predicts daily
fatigue at the level of the individual.
Data analyses were performed using SAS Version 9.4 (Cary, NC). A p value < .05 (twotailed) was considered statistically significant. Based on previous research (Jim et al., 2011;
Rumble et al., 2010), effect sizes for relationships of interest in the present study were expected
to be medium (i.e., r = 0.30). A power analysis using G*Power 3.1 indicated that a sample of 84
patients would be needed to detect significance of a medium effect (r = 0.30) with a Type I error
rate of 0.05 (two-tailed) and power of 0.80. For the regression analyses, a sample size of 84
participants would allow for an effect size of f2 = 0.12 to be detected with 80% power and an
alpha of .05. Assuming an approximate 15% correction for missing data and objective data
recording failure, the present study proposed recruiting 96 participants with 84 providing
complete data. Complete data was defined as data collected from at least two weekdays and a
weekend day for a total of at least three out of seven days of data. Based on higher than
anticipated rates of non-compliance to study design, a total of 117 participants were recruited.
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Results
Recruitment and Patient Characteristics
Figure 1 depicts patient flow through the study. Overall, 513 patients were screened for
eligibility between June 2017 and January 2018. Of these, 335 were excluded from the study due
to: receiving a transplant other than allogeneic HCT (n=95), being less than one year posttransplant (n=88), being greater than five years post-transplant (n=86), having a history of other
malignancy (other than non-melanoma skin cancer, n=25), having recurrence/progression of
disease (n=19), not being proficient in English (n=16), having non-ambulatory status (n=3), not
having cellphone or internet access (n=2), or being deceased (n=1). Of the original 513 patients
screened, 178 patients were deemed eligible and 133 of these patients were invited to participate
in the study.
Of the 133 patients approached, 117 patients consented to the study (88% of eligible
patients). Patients who agreed to participate did not differ from those who declined participation
on the basis of age, gender, ethnicity, or race (all p values > .05). Three patients were deemed
ineligible after consent due to disease progression, three were lost to follow-up, and one
discontinued participation due to feeling too ill to participate. Of the 110 patients who completed
the study, nine did not complete the study questionnaire, while nine did not complete the study
questionnaire on day seven of the study. Six patients failed to provide at least three days of EMA
including at least two weekdays and one weekend day, three patients did not provide at least 72
hours of usable actigraphy data, and one patient never received the text messages, which
delivered the EMA component of the study. The final sample for analytic purposes consisted of
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82 patients. Participants who were included in the final sample (n = 82) were compared to those
who were not (n = 35). Participants who were included in the final sample were older (t = -2.37,
p < .05); the groups did not differ on the basis of gender, ethnicity, or race (all p values > .05).
Demographic characteristics of the sample are presented in Table 1. The majority of
participants were female, non-Hispanic White, and married or living with a partner. The sample
was highly educated with the majority having at least some college. Medical characteristics of
the sample are presented in Table 2. At the time of study entry, participants were an average of
2.5 years post-transplant. The majority was diagnosed with leukemia (56%) and received
transplanted cells from a matched unrelated donor (66%). Half the participants received a
myeloablative regimen and half did not. Sixty percent of participants had been diagnosed with
stage I or II acute GVHD, and a majority of participants were diagnosed with mild (22%) or
moderate (39%) chronic GVHD.
Table 3 presents descriptive statistics including means and standard deviations for
participant self-reported sleep disruption (PSQI), symptoms (Lee cGVHD Scale), and quality of
life (FACT-BMT). On average, participants reported relatively high levels of sleep disruption as
measured by the PSQI global sleep score (M = 8.15, SD = 4.32). Seventy-eight percent of
participants scored a 5 or greater indicating clinically significant sleep disruption.
Data from the MSQ were dropped from the present study due to the large percentage of
missing responses. Missing data on the five MSQ items ranged from 46% to 65%. Specifically,
the minimum percentage of missing data (46% of responses) occurred on item 1 (time spent
sitting while traveling to and from places) on a weekday. The maximum percentage of missing
data (65% of responses) occurred on item 2 (time spent sitting while at work) on a weekend day.
Participant-reported activities from the categories on the activities questionnaire were as follows:
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leisure activities within the home (38%), leisure activities outside the home (21%), working
outside the home (17%), other (14%), working within the home (10%).
Table 4 presents descriptive statistics including means and standard deviations for sleep
disruption and activity variables obtained via actigraphy. On average, participants demonstrated
poor sleep efficiency (M = 78.93, SD = 8.88). While participants on average were able to fall
asleep within at least 10 minutes (M = 8.61, SD = 6.83) and slept for 6.7 hours (M = 399.64
minutes, SD = 63.64), they were awake after initially falling asleep for an average of 99.29
minutes (SD = 50.41) during the night. On average, participants spent a considerable percentage
of their time engaged in sedentary activity (M = 55.41%, SD = 10.19), light activity (M =
35.86%, SD = 8.58), or moderate activity (M = 8.73%, SD = 4.37), but not vigorous activity or
very vigorous activity.
Aim 1: Prevalence and Daily Variability of Fatigue Among HCT Recipients
Figure 2 depicts the daily fatigue means for ratings of momentary fatigue, fatigue
interference, most fatigue, and average fatigue. Table 5 presents descriptive statistics including
means and standard deviations for aggregated daily fatigue and summary fatigue variables.
Aggregated daily fatigue mean scores were as follows: 3.57 (SD = 1.91) for momentary fatigue,
4.69 (SD = 2.05) for fatigue interference, 3.25 (SD = 1.71) for most fatigue, and 2.51 (SD = 2.01)
for average fatigue. Summary fatigue mean scores as measured by the FSI were as follows: 3.54
(SD = 1.97) on fatigue severity, 2.47 (SD = 2.06) on fatigue interference, 5.26 (SD = 2.22) on
number of days fatigued, and 3.73 (SD = 2.38) on fatigue per day. Forty-five percent of
participants met or exceeded the clinically significant cut point of 4 on the FSI severity subscale.
Table 6 presents univariate relationships between all fatigue variables and objectively
assessed sleep disruption and sedentary behavior as well as self-reported sleep disruption,
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symptoms, and quality of life. Consistently strong relationships were evident between self-report
measures of sleep disruption, quality of life, and GVH symptoms and measures of aggregated
daily fatigue and summary fatigue (all p values < .001). Similarly, significant relationships were
observed between sleep efficiency and measures of aggregated daily fatigue and summary
fatigue (all p values < .05) except for momentary fatigue and FSI duration (# of days) (p values >
.05). Less consistent relationships were evident between actigraphy-assessed activity indices and
fatigue. Sedentary time was associated with average fatigue (p < .05) and FSI interference (p <
.01), but no other fatigue indices (p values > .05).
Actigraphy-assessed sleep efficiency was correlated with PSQI-assessed global sleep (r =
-0.32, p < .01). Corresponding relationships between self-reported sedentary behavior, as
measured by the MSQ, and actigraphy-assessed sedentary behavior could not be determined due
to the extent of missing MSQ data.
Aim 2: Relative Contribution of Aggregated Daily Fatigue and Summary Fatigue to Aggregated
Sleep Disruption
Relationships of actigraphy-assessed sleep efficiency with sociodemographic and medical
characteristics are presented in Table 7. Participants who were married or partnered, were white,
and had at least some college education scored higher on sleep efficiency as assessed by
actigraphy (all p values < .10). Therefore, these demographic factors were controlled for in
subsequent analyses with sleep efficiency as the outcome.
Relationships among aggregated daily fatigue variables and summary fatigue variables
were preliminarily examined and are presented in Table 8. The relationship between aggregated
momentary fatigue and FSI-measured summary fatigue severity was unexpectedly strong (r =
.90, p < .001). Corresponding relationships among other aggregated daily fatigue variables and

24

other summary fatigue variables were similarly high (see Table 8). The high degree of
collinearity among these variables precluded conducting the original planned analyses for Aim 2
and, therefore, an alternate strategy was developed.
The revised analyses included two sets of models with summary fatigue and aggregated
daily fatigue predicting aggregated sleep disruption, respectively. Results are presented in Table
9. In the first set of models in which summary fatigue was used to predict sleep disruption, all
demographic and clinical variables significantly (p < .10) related to aggregated sleep efficiency
were first entered. Summary fatigue was then entered to determine the variance in sleep
efficiency accounted for by summary fatigue above and beyond these demographic and clinical
variables. Specifically, in the first step, dichotomized versions of marital status, race, and
educational status were entered and were found to account for 13% of the variance in sleep
efficiency, F(3, 78) = 5.17, p < .01. In the second step, summary fatigue accounted for an
additional 9% of the variance in sleep efficiency ( = -0.30, p < .01).
In the second set of models in which aggregated daily fatigue was used to predict
aggregated sleep efficiency, all demographic and clinical factors significantly (p < .10) related to
aggregated sleep disruption were first entered. Aggregated daily fatigue was then entered to
determine the variance in aggregated sleep efficiency accounted for by aggregated daily fatigue
above and beyond these demographic and clinical variables. Once again, dichotomized versions
of marital status, race, and educational status were found to account for 13% of the variance in
sleep efficiency, F(3, 78) = 5.17, p < .01. In the second step, aggregated daily fatigue accounted
for an additional 1% of the variance in sleep efficiency ( = -0.13, p > .05).
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Aim 3: Relative Contribution of Aggregated Daily Fatigue and Summary Fatigue to Aggregated
Sedentary Behavior
Relationships of aggregated sedentary behavior with sociodemographic and medical
characteristics are presented in Table 7. No significant relationships were observed between
aggregated sedentary behavior and sociodemographic or medical factors (all p values > .18).
Therefore, no covariates were included in the Aim 3 analyses. Like Aim 2, the high degree of
collinearity among aggregated daily fatigue and summary fatigue precluded conducting the
original planned analyses for Aim 3 and, therefore, an alternate strategy was developed.
Univariate correlations are presented in Table 6. Here, we present similar analyses using
regression.
The refined analyses included two models, results for which are presented in Table 10. In
the first model, summary fatigue was entered as the only predictor to determine the variance in
aggregated sedentary behavior accounted for by summary fatigue. Summary fatigue accounted
for 1% of the variance in sedentary behavior, F(1, 80) = 2.02, p = .16.
In the second model, aggregated daily fatigue was entered as the only predictor to
determine the variance in aggregated sedentary behavior accounted for by aggregated daily
fatigue. Aggregated daily fatigue accounted for no measurable variance in aggregated sedentary
behavior, F(1, 80) = 0.75, p = .39.
Aim 4: Association of Sleep Disruption and Sedentary Behavior with Evening Reports of Fatigue
These analyses investigated the hypothesis that daily sleep disruption or sedentary
behavior as measured by actigraphy would be related to daily reports of fatigue. These analyses
were carried out using multi-level modeling, a statistical approach to longitudinal data analyses.
Using these models, we are able to distinguish between-person variance (differences in average
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scores) from within-person variance (fluctuations in scores from a person’s average). The
analyses focused on one set of same-day relationships (i.e., the relationship between sedentary
behavior and daily fatigue) and one set of lagged relationships (i.e., how sleep efficiency predicts
the next evening’s daily fatigue) with two outcome variables of interest (i.e., daily momentary
fatigue and daily average fatigue) for each set. Lagging was achieved through study design and
database set-up, which coded the first night of sleep as a day 1 variable. Therefore, no statistical
lagging had to be done. In these analyses, the Aim 4 predictors were separately grand-mean
centered at the sample mean and person-centered at the person-level mean (a person’s usual level
of daily sleep efficiency or sedentary behavior, as represented by each person’s mean across all
seven days of the study).
Variability in daily measures (results from models 1 – 4). Models 1 through 4 provide
information on the total variance in daily actigraphy measures (i.e., sleep efficiency and
sedentary behavior) as well as daily assessments of fatigue (i.e., momentary fatigue and average
fatigue). The total variance is composed of differences between persons in average scores and
differences within persons in the fluctuation of these scores. Table 11 lists the percentages of
between- and within-person relative contribution to the total variance of scores. Results
suggested that the majority of the variance in all variables was driven by between-person
differences in average scores; however, there was sufficient within-person variation to proceed
with planned analyses.
Concurrent analyses with sedentary behavior predicting daily fatigue (results from
models 5 – 6). Results from these analyses are displayed in Table 12. Results from model 5,
which focused on between-person differences in average scores, revealed that participants who
on average were more sedentary during the day had higher evening reports of average daily
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fatigue ( = 4.44, p < .05) but not momentary fatigue ( = 1.56, p > .05). Results from model 6,
which focused on adding in the within-person fluctuation in scores, revealed that at times when
sedentary behavior was higher than usual for individuals, evening reports of average daily
fatigue were also higher than usual ( = 3.92, p < .01). This finding did not extend to results with
momentary fatigue ( = -0.58, p > .05).
Time-lagged analyses with sleep efficiency predicting daily fatigue (results from models 5
– 6). Results from these analyses are displayed in Table 12. Results from model 5, which focused
on between-person differences in average scores, revealed that participants who on average
experienced less efficient sleep had higher reports of average daily fatigue ( = -0.09, p < .001)
but not momentary fatigue ( = -0.04, p > .05) the next evening. Results from model 6, which
focused on adding in the within-person fluctuation in scores, revealed that at times when sleep
efficiency was lower than usual for individuals, reports of average daily fatigue were higher than
usual the next evening ( = -0.02, p < .05). This finding did not extend to results with
momentary fatigue ( = -0.02, p > .05).
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Discussion
The present study sought to characterize daily fatigue and the relationships of
objectively-assessed sleep disruption and sedentary behavior with patient-reported fatigue among
allogeneic HCT recipients who were one to five years post-transplant. Results demonstrated that
allogeneic HCT recipients continue to struggle with fatigue in the post-treatment period. Fortyfive percent of participants met criteria for clinically significant fatigue on a retrospective fatigue
measure. Of note, fatigue severity was unrelated to time since transplant. This estimate exceeds
reports from previous studies that between 11 to 35% of HCT recipients meet criteria for
clinically significant fatigue three or more years after transplant (Jim et al., 2016; Gielissen et al.,
2007; Hjermstad et al., 2004). In the present study, daily assessments of fatigue using an EMAlike approach were similarly high. The only other study to our knowledge to use an EMA
approach for fatigue assessment among transplant recipients assessed fatigue prior to transplant
and, again, in the acute period after transplant (Hacker et al., 2007). That study reported that a
minority of patients reported clinically significant fatigue prior to transplant; however, a large
majority met criteria after transplant.
A major focus of the present study was examination of relationships of aggregated daily
and summary fatigue with actigraphy-assessed sleep disruption and sedentary behavior. It was
hypothesized that aggregated daily fatigue would predict aggregated actigraphy-assessed sleep
disruption and sedentary behavior over and above summary fatigue. However, the unexpectedly
high multicollinearity among the aggregated daily and summary fatigue variables precluded our
ability to carry out planned analyses. While relationships among the fatigue variables were
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expected to be strong, relationships at times exceeded r = .90. There are several possible
explanations. First, the strength of these relationships may simply be reflective of the
phenomenological experience and pattern of fatigue for allogeneic transplant recipients beyond
one year post-transplant. Second, wording for the daily assessments of fatigue borrowed heavily
from the summary fatigue measure. This feature may have increased participants’ awareness of
their daily fatigue thereby impacting their summary fatigue scores on the FSI. Third, participants
were one to five years post-HCT and were not undergoing active treatment. This feature may, in
part, account for the lack of variability in daily ratings of fatigue, resulting in greater
correspondence between daily and summary ratings of fatigue.
Though not ideal, revised analyses focused on developing separate models of the ability
of aggregated daily fatigue and summary fatigue in predicting actigraphy-assessed sleep
disruption and sedentary behavior. Summary fatigue, but not aggregated daily fatigue, was found
to be predictive of aggregated sleep efficiency. In contrast, neither aggregated daily fatigue nor
summary fatigue was found to be predictive of aggregated sedentary behavior.
The original hypotheses with regard to this aspect of the study were based on work
suggesting that autobiographical memory and recall processes are prone to bias, which can
adversely impact the validity of retrospective self-report ratings (Shiffman, Stone, & Hufford,
2008). Despite the large body of evidence supporting these underlying processes, these sources
of bias within retrospective measures, if present, did not hold in the present study. To our
knowledge, there are no studies with transplant recipients or cancer patients with which to
directly compare these results, making interpretation within a larger literature difficult. It is
possible that sources of bias may be more influential when measuring symptomatology during
times within which there is more variability in daily fatigue and other symptoms (e.g., while
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undergoing active treatment). As already mentioned, it is also possible that underlying sources of
bias were minimized in the present study because participants were asked to provide daily
assessments of symptom experience thereby making their daily experience of symptoms more
salient in recall. While there are a number of factors specific to the present study’s design that
could influence results, these findings preliminarily suggest that an EMA methodology does not
present an advantage over traditional retrospective measures in cases where symptoms assessed
daily are aggregated over time.
As part of the current study, it was theorized that memory bias and heuristics in
combination with the temporal gap which occurs between objectively recording behavior and
assessing symptoms with summary measures, could partially account for the mixed evidence in
relationships between self-reported symptoms and objectively-assessed behavior. The present
study sought to evaluate whether EMA-based symptom assessment, in offering an advantage of a
closer temporal measurement to objectively assessed behavior, would yield more consistent
relationships than summary measures between self-reported symptoms and objectively assessed
behaviors. Findings suggest that the temporal gap may not explain mixed results and that future
research should investigate other factors (e.g., population and treatment factors) that may
account for the difference in relationships. Despite lack of evidence for advantages of an EMAbased assessment approach, these findings are encouraging in that they provide support for the
existing body of work that has relied on traditional retrospective measures of symptom
experience. This is potentially important information for researchers designing studies of
symptoms in cancer patients and good news for patients in terms of maintaining low participant
burden.
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An exploratory aim of the present study was to evaluate whether an individual would be
likely to rate themselves as more fatigued after nights with greater sleep disruption or days with
greater sedentary behavior, as compared to times when their sleep was less disrupted and they
were more active. To answer this question, sources of variability in study predictors and
outcomes were first explored. These analyses revealed that the daily fatigue measures showed
significant variability, with persons varying from one another and across days over the seven-day
study period. Relationships between sedentary behavior, sleep efficiency, and fatigue at the
group level were then assessed and showed that individuals who were more sedentary and had
less efficient sleep were more likely to rate themselves as more fatigued on average. Finally, at
times when persons were more sedentary than usual or had less efficient sleep than usual, they
were more likely to rate their average level of fatigue as greater than usual. The literature is
mixed with regard to associations between objectively measured behavior and self-reported
symptoms. Although some studies have found no relationships (e.g., Fernandes et al., 2006),
findings from the present study are in line with a growing number of studies demonstrating links
between objectively measured behavior and self-reported fatigue among cancer patients using a
daily analysis approach (Jim et al., 2013; Jim et al., 2011) and more traditional summary
approaches (Shen et al., 2016; Liu et al., 2012; Berger et al., 2010; Berger et al., 2007; Sarna &
Conde, 2001). Results from the present study were obtained through the use of sophisticated
modeling techniques capable of identifying and elucidating relationships at the group-level as
well as at the person-level. These findings represent an important addition to previous literature
and warrant replication and further study.
These observed relationships were demonstrated with average fatigue as the outcome;
corresponding relationships with momentary fatigue as the outcome were not significant. This
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pattern of results suggests that patients’ summaries of fatigue for the day may be more
meaningful than a single, momentary rating when conducting a daily analysis of relationships
with actigraphy-assessed behavior. Moreover, these findings highlight the need for researchers to
carefully choose variables apriori based on theory and a close review of previous literature.
Although this methodology does not overcome the problem of examination of cross-sectional
relationships, this approach begins to untangle these relationships by modeling temporal relations
between how sedentary people are and how well they sleep and their related experience of
fatigue.
It was originally theorized that aggregated daily assessments of fatigue would explain
additional variability in objectively-assessed sleep and sedentary behavior beyond that accounted
for summary measures of fatigue. As noted previously, this expectation was based on EMA
approaches collecting real-time data with repeated sampling over time and not asking patients to
retrospectively aggregate experience. Although these hypotheses could not be tested due to the
high collinearity between aggregated daily and summary measures of fatigue, results from the
present study suggest that EMA assessments of symptoms may still be valuable in select
circumstances. Findings from the present study suggest that an EMA approach to measurement is
useful in studies assessing day-to-day fluctuation in symptoms and daily analysis of relationships
among fluctuating symptoms. Results suggest that interindividual differences, at the group level,
and intraindividual differences, at the person level, in the relationship between sleep efficiency
or sedentary behavior and daily fatigue are both important for understanding how these factors
relate to one another. Use of EMA assessments of symptoms under these conditions allows for a
more sophisticated understanding of the contribution of behavioral factors to cancer-related
fatigue. This approach may also aid in improved identification of intervention targets for
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addressing cancer-related fatigue. Therefore, EMA represents methodology that is
complementary to retrospective patient self-report and which may be better able to address
certain research questions.
The present study had several limitations. First, the study was slightly underpowered with
a final sample of 82 participants instead of 84 as indicated by power analyses. Second, and as
already discussed, the high collinearity among fatigue indices led to changes in planned analyses.
Third, the large amount of missing MSQ data precluded our ability to assess relationships
between objectively-assessed and self-reported sedentary behavior. Finally, it is possible that
daily assessments of fatigue may have influenced participants’ responses on the summary fatigue
measure. Despite these limitations, the present study adds to existing literature characterizing
fatigue among patients who have received allogeneic HCT. In addition to collecting retrospective
reports of fatigue, the current study examined daily reports of fatigue using an EMA-based
measurement approach. Moreover, the study characterized sleep and activity behavioral patterns
using actigraphy, a methodology that complements use of self-report measures in providing a
more complete picture of these behaviors in real time.
Results from this study suggest several future directions. First, further exploration into
daily relationships among sleep, activity, and fatigue is needed. To date, most studies that have
looked at these relationships have done so at the group level; results from the present study
suggest that interindividual and intraindividual variation are both important for gaining a richer
understanding of the complexity of these factors and how they relate. Second, results support
conducting research investigating the efficacy of interventions focused on ameliorating sleep
disruption and reducing sedentary activity as means for lessening the severity and impact of
fatigue on daily life in patients who have undergone HCT. While a majority of participants in the
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present study did not meet criteria for clinically significant fatigue, a large minority continued to
struggle with fatigue. Moreover, results from the present study suggest that many patients were
sedentary for considerable periods of time and were experiencing disrupted sleep. Both of these
behaviors should be targeted for intervention. Results from the present study further suggest that
accelerometers represent a valuable methodology for measurement of behaviors alongside
traditional self-report methods and should be incorporated into intervention research.
In conclusion, the present study adds to previous literature examining fatigue and its
relationship with sleep and activity in a cancer population. Additionally, the study evaluates the
relative merits of retrospective versus daily approaches to assessing fatigue. Major findings were
that: nearly half of patients one to five years post-transplant experience clinically significant
fatigue; retrospective measures continue to be valuable tools for assessing relationships of
fatigue with actigraphy-assessed behavior; daily assessments of patient symptoms represent a
valuable tool for exploring person-level relationships between fatigue and actigraphy-assessed
behaviors. In addition to providing support for both retrospective and daily approaches to
assessing fatigue, findings identify behavior targets (i.e., sedentary behavior and sleep
disruption) for interventions designed to address cancer-related fatigue.
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Table 1. Demographic Characteristics (N = 82)
Characteristic

n (%)

Age, years
M (SD)
Range

56 (11.7)
25 - 74

Gender, No. (%)
Male
Female

39 (47.6)
43 (52.4)

Ethnicity, No. (%)
Not Hispanic
Hispanic

75 (91.5)
7 (8.5)

Race, No. (%)
White
Nonwhite

75 (91.5)
7 (8.5)

Marital Status, No. (%)
Married or living with partner
Not married

60 (73.2)
22 (26.8)

Education, No. (%)
High school or less
College or more

14 (13.4)
68 (86.6)

Employment, No. (%)
Work full-time or part-time
Retired
Disabled
Other

26 (31.7)
26 (31.7)
23 (28.1)
7 (8.5)

Income, No. (%)
< 40K
≥ 40K

24 (29.3)
58 (70.7)

Functional Status, No. (%)
0
1
2
3
4

32 (39.1)
42 (51.2)
7 (8.5)
1 (1.2)
0 (0.0)
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Table 2. Medical Characteristics (N = 82)
Characteristic

n (%)

Cancer type, No. (%)
Leukemia
Non-Hodgkin lymphoma
Myelodysplastic Syndrome
Multiple Myeloma
Myeloproliferative Syndrome
Other

46 (56.1)
14 (17.1)
7 (8.5)
6 (7.3)
5 (6.1)
4 (4.9)

Ablation, No. (%)
Myeloablative
Non-myeloablative

41 (50.0)
41 (50.0)

Donor type, No. (%)
Related
Matched Unrelated

28 (34.1)
54 (65.9)

Time since transplant, days
M (SD)
Range

942 (449.3)
370 - 1889

aGVHD grade, No. (%)
0
I – II
III – IV
Unknown

26 (31.7)
49 (59.8)
4 (4.9)
3 (3.6)

cGVHD grade, No. (%)
None
Mild
Moderate
Severe
Unknown

24 (29.3)
18 (22.0)
32 (39.0)
7 (8.5)
1 (1.2)

Note. aGVHD = acute graft-versus-host disease, cGVHD = chronic graft-versus-host disease.
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Table 3. Descriptive Statistics for Sleep Disruption and Symptoms
Variables

n

Score range
possible

M (SD)

Min

Max

Global sleep

82

0 – 10

8.15 (4.02)

1

18

Sleep duration

81

0–3

0.42 (0.70)

0

3

Nighttime disturbance

77

0–3

1.82 (0.76)

0

3

Sleep latency

76

0–3

1.38 (1.03)

0

3

Daytime dysfunction

82

0–3

1.22 (0.80)

0

3

Sleep efficiency

81

0–3

0.99 (1.08)

0

3

Sleep quality

82

0–3

1.26 (0.68)

0

3

Sleep medication use

82

0–3

1.10 (1.35)

0

3

cGVHD

81

0 – 120

18.30 (11.65)

0

68

FACT-BMT

81

0 – 92

67.88 (11.07)

23

89

Sleep Disruption

Symptoms

Note. All sleep disruption items derived from the PSQI. cGVHD = chronic graft-versus-host
disease. FACT-BMT = functional assessment of cancer therapy-BMT specific subscale.
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Table 4. Actigraphy Descriptive Statistics (N = 82)
Variables

M (SD)

Min

Max

Sleep efficiency, %

78.93 (8.88)

51.79

93.19

SOL, min

8.61 (6.83)

0.43

28.57

WASO, min

99.29 (50.41)

24.86

288.86

TST, min

399.64 (63.64)

252.57

541.43

Sedentary time, %

55.41 (10.19)

36.22

77.45

Light time, %

35.86 (8.58)

15.24

53.84

Moderate time, %

8.73 (4.37)

0.50

24.90

Vigorous time, %

0.00 (0.00)

0.00

0.00

Very vigorous time, %

0.00 (0.00)

0.00

0.00

Sleep disruption

Sedentary behavior

Note. All variables listed were aggregated across the 7 study days. SOL = Sleep onset latency
which is represented in minutes, WASO = wake after sleep onset which is represented in
minutes, TST = total sleep time which is represented in minutes, Sedentary time = percent spent
in sedentary activity, Light time = percent spent in light activity, Moderate time = percent spent
in moderate activity, Vigorous time = percent spent in vigorous activity, Very vigorous time =
percent spent in very vigorous activity.
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Table 5. Fatigue Descriptive Statistics (N = 82)
Variables

Score range
possible

M (SD)

Min

Max

Momentary fatigue

0 – 10

3.57 (1.91)

0

7.6

Fatigue interference

0 – 10

4.69 (2.05)

0

8.5

Most fatigue

0 – 10

3.25 (1.71)

0

7.75

Average fatigue

0 – 10

2.51 (2.01)

0

7.83

FSI severity

0 – 10

3.54 (1.97)

0

8.5

FSI interference

0 – 10

2.47 (2.06)

0

8.0

FSI duration (# of days)

0–7

5.26 (2.22)

0

7.0

FSI duration (per day)

0 – 10

3.73 (2.38)

0

10.0

Aggregated daily fatigue

Summary fatigue

Note. Aggregated daily fatigue items were assessed as follows: (1) Momentary fatigue was
assessed by asking patients, “Rate your level of fatigue right now,” (2) Fatigue interference was
assessed by asking patients, “Rate how much did fatigue interfere with your general level of
activity today,” (3) Most fatigue was assessed by asking patients, “Rate your level of fatigue at
the time you felt most fatigued today,” and (4) Average fatigue was assessed by asking patients,
“Rate your average level of fatigue today.” FSI = Fatigue Symptom Inventory.
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Table 6. Pearson Correlation Coefficients of Fatigue Variables with Sedentary Behavior, Sleep,
and Symptom Variables
Variables

Momentary
fatigue

Fatigue
interference

Most
fatigue

Average
fatigue

FSI
severity

FSI
interference
0.26**

FSI
duration
(# of days)
0.01

FSI
duration
(per day)
0.16

Sedentary
time
Light time

0.10

0.11

0.15

0.23*

0.16

-0.08

-0.06

-0.14

-0.23*

-0.14

-0.22*

0.08

-0.12

Moderate
time
Sleep
efficiency
SOL

-0.06

-0.13

-0.09

-0.08

-0.10

-0.17

-0.18

-0.13

-0.17

-0.24*

-0.35**

-0.37***

-0.37***

-0.29**

-0.17

-0.31**

-0.07

0.02

-0.00

0.11

0.06

0.05

0.12

0.14

WASO

0.26*

0.32**

0.42***

0.44***

0.43***

0.33**

0.17

0.34**

TST

0.10

0.05

-0.03

0.00

0.00

0.03

-0.07

-0.04

PSQI
Global

0.40***

0.40***

0.49***

0.57***

0.50***

0.52***

0.29**

0.52***

cGVHD

0.47***

0.45***

0.44***

0.54***

0.56***

0.59***

0.41***

0.56***

FACTBMT

-0.49***

-0.44***

-0.47***

-0.54***

-0.56***

-0.61***

-0.38***

-0.49***

Note. * p < .05, ** p <.01, *** p < .001. Sedentary time = percent spent in sedentary activity,
Light time = percent spent in light activity, Moderate time = percent spent in moderate activity,
SOL = Sleep onset latency, WASO = wake after sleep onset, TST = total sleep time. PSQI =
Pittsburgh sleep quality inventory. cGVHD = chronic graft-versus-host disease. FACT-BMT =
functional assessment of cancer therapy-BMT specific subscale
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Table 7. Point Biserial Correlations Between Study Outcomes and Sociodemographic and
Medical Variables

Sociodemographic
Variables
Gender (Female)

Aggregated sleep
efficiency
rpb
p

Aggregated
sedentary time
rpb
p

0.05

.68

-0.04

.73

Ethnicity (Hispanic)

-0.04

.72

0.13

.23

Race (White)

0.19

.09

0.04

.75

Marital Status (Married)

0.31

.004

-0.05

.67

Education (Some College)

0.29

.008

0.15

.18

Employment (Working)

0.08

.49

-0.14

.22

Age

0.14

.20

0.14

.22

Days Post Transplant

-0.13

.25

-0.15

.19

Note. Significant relationships (p < .10) are bolded and were controlled for in hierarchical
regression models. Aggregated sleep efficiency and aggregated sedentary time were both derived
from actigraphy.
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Table 8. Pearson Correlation Coefficients Among Fatigue Indices
Variables

FSI severity

FSI interference
0.76

FSI duration
(# of days)
0.57

FSI duration
(per day)
0.74

Momentary fatigue

0.90

Fatigue interference

0.90

0.74

0.66

0.73

Most fatigue

0.90

0.76

0.66

0.73

Average fatigue

0.85

0.84

0.54

0.77

Note. All bolded items indicate p < .001.
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Table 9. Aim 2 Multivariable Hierarchical Regression Models with Sleep Efficiency as an
Outcome
R2



p

0.13

-

-

White

-

0.14

.17

Married

-

0.24

.03

College educated

-

0.22

.04

0.22

-

-

White

-

0.13

.20

Married

-

0.21

.05

College educated

-

0.19

.07

FSI severity

-

-0.30

.003

0.13

-

-

White

-

0.14

.17

Married

-

0.24

.03

College educated

-

0.22

.04

0.14

-

-

White

-

0.15

.17

Married

-

0.23

.03

College educated

-

0.21

.05

Momentary fatigue

-

-0.13

0.22

Predictors

Model 1

Step 1

Step 2

Model 2

Step 1

Step 2

Note. All bolded items indicate p < .05. FSI severity = summary fatigue, Momentary fatigue =
aggregated daily fatigue.
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Table 10. Aim 3 Multivariable Hierarchical Regression Models with Sedentary Time as an
Outcome

Model
1

Step 1

Model
2

Predictors

Step 1

FSI severity

Momentary fatigue

R2



p

0.01

-

-

-

0.16

.16

-0.00

-

-

-

0.10

.39

Note. All bolded items indicate p < .05. FSI severity = summary fatigue, Momentary fatigue =
aggregated daily fatigue.
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Table 11. Aim 4 Models 1 through 4 - Variability
Daily Variables

Percent of Total BetweenPerson Variance (ICC)
56%

Percent of Total WithinPerson Variance
44%

Average fatigue

57%

43%

Sedentary time

71%

29%

Sleep efficiency

60%

40%

Momentary fatigue
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Table 12. Aim 4 Models 5 and 6 - Predictors
Momentary fatigue

Average fatigue



p



p

Sedentary time

1.56

.45

4.44

.04

Model 6

Sedentary time

-0.58

.63

3.92

.002

Model 5

Sleep efficiency

-0.04

.07

-0.09

<.001

Model 6

Sleep efficiency

-0.02

.17

-0.02

.04

Models

Predictors

Model 5

Note. All bolded items indicate p < .05.
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Enrollment

Screened (n=513)
Excluded (n=335)
• HCT other than allogeneic (n=95)
• <1 year post-HCT (n=88)
• >5 years post-HCT (n=86)
• History of other malignancies
(n=25)
• Recurrence/Progression (n=19)
• Non-English speaking (n=16)
• Non-ambulatory status (n=3)
• No cellphone/internet access (n=2)
• Deceased (n=1)

Eligible (n=178)
Eligible/Pending at time of study close
(n=34)
Could not be reached / No appointment
(n=11)
Approached (n=133)
• Refused in clinic (n=16)

Study Period

Consented (n=117)
Ineligible after consent (disease progression;
n=3)
Lost to follow-up (n=3)
Discontinued participation (n=1)

Completed Study (n=110)

Analysis

Included in Analysis
Figure 1. Flow Diagram
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Excluded from analysis (n=28)
• Did not complete questionnaire
(n=9)
• Completed questionnaire day other
than day 7 (n=9)
• EMA criteria not met (n=6)
• No actigraphy data (actigraph
recording failure, actigraph never
(n=82) returned, n=3)
• Technology failure
(patient never received
texts, n = 1)

10
9
8

Daily
Fatigue

7
6
5
4
3
2
1
0

Day 1
Momentary fatigue 4.61
Fatigue interference 5.47
Most fatigue
3.7
Average fatigue
3.13

Day 2
3.53
4.84
3.31
2.56

Day 3
3.72
4.71
3.37
2.41

Figure 2. Daily Fatigue Means
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Day 4
2.95
4.48
2.99
2.17

Day 5
3.26
4.18
2.99
2.32

Day 6
3.32
4.53
3.01
2.37

Day 7
3.34
4.35
3.15
2.51
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Appendix B

Contribution of Sleep Disruption and
Physical Inactivity to Fatigue In Survivors of
Allogeneic Hematopoietic Cell Transplant
Patient Questionnaire

Study ID#:

Date Completed:

/

/

For questions or comments, please contact:
Ashley Nelson, M.A.
Research Coordinator
Health Outcomes and Behavior, MRC-PSY
Moffitt Cancer Center
12902 Magnolia Drive
Tampa, FL 33612
Telephone #: 1-800-456-3434 ext. 4606
Ashley.Nelson@moffitt.org
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GBI
1. Today’s Date:

/

2. Date of Birth:

/

/

/
/

(MM/DD/YYYY)

/

(MM/DD/YYYY)

3. Age:
4. Gender:

Male

Female

5. Ethnic Group:

Hispanic/Spanish/Latino

Not Hispanic/Spanish/Latino

6. Racial Background (check one):
c

Black/African American American

Indian or Alaskan Native

White/Caucasian

Native Hawaiian/Pacific Islander

Asian

More than one race (specify):_________________

7. Marital status:
Married or living with partner

Divorced

Single

Separated

Widowed

8. Completed Education:
Less than 12 years

Trade school

College graduate

High school graduate

Some college

Post-graduate degree

9. Current Employment Situation (check the one box that applies the most):
Working full time

Working part time

Seeking work

On leave with pay

On leave without pay

Disabled

Student

Homemaker

Retired

10. What is your approximate annual gross income:

63

Less than $10,000

$20,000 - $39,999

$60,000 - $100,000

$10,000 - $19,999

$40,000 - $59,999

Greater than $100,000

Prefer not to answer
11. What is your height? __________
12. What is your weight (in pounds)?
13. Please check the box next to the option that describes your current level of activity:
Fully active, able to carry on all pre-disease performance without restriction.
Restricted in physically strenuous activity but ambulatory and able to carry out work of a
light or sedentary nature, e.g. light housework, office work.
Ambulatory and capable of self care, but unable to carry out any work activities. Up and
about more than 50% of waking hours.
Capable of only limited self care, confined to bed or chair more than 50% of waking hours.
Completely disabled. Cannot carry on any self care. Totally confined to bed or chair.
14. Have you used any prescription or non-prescription medications to help with sleep in the past
30 days? ____ Yes

____ No

If yes, what medication(s) have you taken? ___________________________________________
______________________________________________________________________________
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Activity Report
Instructions: Circle the one response that best matches your main daily activity on each day
you wore the study watch.
Day 1
Working outside the home

Working within the home (at home job)

Leisure activities outside the home

Leisure activities within the home

Other, please describe: ____________________________________________________

Day 2
Working outside the home

Working within the home (at home job)

Leisure activities outside the home

Leisure activities within the home

Other, please describe: ____________________________________________________

Day 3
Working outside the home

Working within the home (at home job)

Leisure activities outside the home

Leisure activities within the home

Other, please describe: ____________________________________________________

Day 4
Working outside the home

Working within the home (at home job)

Leisure activities outside the home

Leisure activities within the home

Other, please describe: ____________________________________________________

Day 5
Working outside the home

Working within the home (at home job)

Leisure activities outside the home

Leisure activities within the home

Other, please describe: ____________________________________________________
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Day 6
Working outside the home

Working within the home (at home job)

Leisure activities outside the home

Leisure activities within the home

Other, please describe: ____________________________________________________

Day 7
Working outside the home

Working within the home (at home job)

Leisure activities outside the home

Leisure activities within the home

Other, please describe: ____________________________________________________
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Appendix C
Daily Ratings

1. Rate your level of fatigue right now:

□ □ □

□

□

□

□

□

□ □ □

Not at all
fatigued

As fatigued
as I could be

2. Rate how much fatigue interfered with your general level of activity today:

□ □ □

□

□

□

□

□

□ □ □

No
interference

Extreme
interference

3. Rate your level of fatigue at the time you felt most fatigued today:

□ □ □

□

□

□

□

□

□ □ □

Not at all
fatigued

As fatigued
as I could be

4. Rate your average level of fatigue today:

□ □ □

□

□

□

□

□

□ □ □

Not at all
fatigued

As fatigued
as I could be

5. What time did you go to bed last night with the intent to fall asleep?

:

6. What time did you wake up this morning?
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:

